RxDoctor Payments Data

Mary Chance

Family · Kingfisher, OKNPI 1083190896

Payments from drug & device makers

$2,555in general payments, 2019–2025

Across 162 payments — averaging $15.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$526
  • Boehringer Ingelheim$178
  • Otsuka America Pharmaceutical, Inc.$172
  • Axsome Therapeutics, Inc.$150
  • AstraZeneca$149
  • Biohaven Pharmaceutical Holding Company Ltd.$143
  • plus $1K from 26 others

What the payments were for

  • Food & beverage$2,555100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,555 in reported general payments places this provider in the 85th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide31$33,587
EliquisApixaban20$13,305
OzempicSemaglutide13$11,822
JardianceEmpagliflozin16$11,783
RybelsusSemaglutide11$9,422
Albuterol Sulfate HfaAlbuterol Sulfate25$658
Atorvastatin Calcium59$513
Omeprazole19$432
Levothyroxine Sodium42$378
Duloxetine Hcl13$354
Celecoxib24$291
Gabapentin38$272
Lisinopril35$209
Enalapril Maleate14$205
Fluticasone Propionate18$193

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$132$33,58731 claims
Novo NordiskOzempic, Rybelsus$73$21,24424 claims
PfizerEliquis$137$13,30520 claims
Boehringer IngelheimJardiance$178$11,78316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,026 family providers in Oklahoma.

Other family in Kingfisher

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →